Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs 4,713
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Pipeline programs

Page 7 of 99

  1. 68Ga-Pentixafor

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 1 small molecule active

    1 trial

  2. 70035108EDI1001

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  3. 70218902EDI1001

    Janssen-Cilag International N.V.

    Metastatic Castration-Resistant Prostate Cancer

    phase 1 other active

    1 trial

  4. 73841937NSC1001

    Janssen-Cilag International N.V.

    Advanced Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  5. 74856665AML1001

    Janssen-Cilag International N.V.

    Acute myeloid leukemia or Myelodysplastic syndrome

    phase 1 other active

    1 trial

  6. 75276617ALE1002

    Janssen-Cilag International N.V.

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  7. 77242113PSO1007

    Janssen-Cilag International N.V.

    Renal Impairment

    phase 1 other active

    1 trial

  8. 77242113PSO1008

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  9. 77242113PSO1009

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  10. 77242113PSO1010

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  11. 78278343PCR1001

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer

    phase 1 other active

    1 trial

  12. 78278343PCR1003

    Janssen-Cilag International N.V.

    Metastatic Prostate Cancer

    phase 1 other active

    1 trial

  13. 79635322MMY1002

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 1 other active

    1 trial

  14. 80948543LYM1002

    Janssen-Cilag International N.V.

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies

    phase 1 other active

    1 trial

  15. 845900241/0147/1

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a bioavailability study in healthy subjects)

    phase 1 other active

    1 trial

  16. 87189401PCR1001

    Janssen-Cilag International N.V.

    Advanced Prostate Cancer

    phase 1 other active

    1 trial

  17. 88545223PSO1001

    Janssen-Cilag International N.V.

    Psoriasis

    phase 1 other active

    1 trial

  18. 88549968MPN1001

    Janssen-Cilag International N.V.

    CALR-mutated Myeloproliferative Neoplasms

    phase 1 other active

    1 trial

  19. 88998377LYM1001

    Janssen-Cilag International N.V.

    relapsed or refractory B‑cell non-Hodgkin lymphomas

    phase 1 other active

    1 trial

  20. 89853413AML1001

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  21. 89862175LUC1001

    Janssen-Cilag International N.V.

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  22. 89Zr-DFO-YS5

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  23. 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)

    Telix Innovations

    Soft Tissue Sarcoma

    phase 1 small molecule active

    1 trial

  24. 89Zr-Girentuximab

    Telix Innovations

    Urothelial Carcinoma

    phase 1 small molecule completed

    1 trial

  25. 89Zr-Girentuximab

    Telix Innovations

    Clear Cell Renal Carcinoma

    phase 1 other completed

    1 trial

  26. 89Zr-girentuximab

    Telix Innovations

    Carcinoma, Renal Cell

    phase 1 other completed

    1 trial

  27. 89Zr˗DFO˗REGN3504

    Regeneron UK Limited

    Advanced PD-L1 Positive Malignancies

    phase 1 small molecule terminated

    1 trial

  28. 89Zr˗DFO˗REGN5054

    Regeneron UK Limited

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  29. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Refractory Cancer

    phase 1 small molecule terminated

    1 trial

  30. 90014496LYM1001

    Janssen-Cilag International N.V.

    Non-Hodgkin Lymphoid Malignancies

    phase 1 other active

    1 trial

  31. 90106848EDI1001

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  32. 90189892AML1001

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  33. 90301900HNC1001

    Janssen-Cilag International N.V.

    Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

    phase 1 other active

    1 trial

  34. 950P1V02

    Toray International U.K. Limited

    Bladder cancer, Cholangiocarcinoma, Colorectal Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Ovarian Cancer, Palpable Subcutaneous Malignant Lesions, Primary Peritoneal Cancer, Renal Cell Carcinoma, Solid Tumor

    phase 1 other active

    1 trial

  35. 95597528EDI1001

    Janssen-Cilag International N.V.

    Mild to Moderate Asthma

    phase 1 other active

    1 trial

  36. 974/24

    Alphapharm Pty Ltd

    Bioequivalence study in healthy volunteers under fasting conditions

    phase 1 other active

    1 trial

  37. 987/24

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a bioavailability study in healthy subjects).

    phase 1 other active

    1 trial

  38. 988/24

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a bioavailability study in healthy subjects).

    phase 1 other active

    1 trial

  39. 99mTc-QULIC-5-P1

    The First People's Hospital of Lianyungang

    Prostate Cancer Stage

    phase 1 small molecule active

    1 trial

  40. 9MW3811 injection

    Shanghai University of Traditional Chinese Medicine

    Pulmonary Fibrosis

    phase 1 small molecule completed

    1 trial

  41. 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    HPV Infection

    phase 1 mab active

    1 trial

  42. A Clinical Study to Compare the Impact of Mul...

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension

    phase 1 other active

    1 trial

  43. A Mass Balance Study of [14C]-IPN60250 in Healthy Adult Participants

    Ipsen

    Primary sclerosing cholangitis (PSC)

    phase 1 other active

    1 trial

  44. A Multi-arm Phase 1b Study of Teclistamab Wit...

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  45. A Multicentre for High-Risk, Surgically Resectabl…

    Fondazione Telethon ETS

    High-Risk, Surgically Resectable Melanoma

    phase 1 other active

    1 trial

  46. A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants

    Merck Sharp and Dohme

    Amyotrophic lateral sclerosis and Alzheimer’s disease

    phase 1 other active

    1 trial

  47. A Phase 1 Open-label Study to Assess the Safety for Solid Tumors

    Pasithea Therapeutics

    Solid Tumors

    phase 1 other active

    1 trial

  48. A Phase 1 Study of HMPL-306 in Locally Advanced Solid Tumors with IDH mutations

    Hutchmed Europe B.V.

    - Locally advanced or metastatic solid tumors - Cholangiocarcinoma - Skeletal chondrosarcoma - Low-grade glioma - Any other solid tumor harboring an IDH mutation

    phase 1 other active

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.